Outcomes of Focal Therapies for Prostate Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | January 2, 2018 |
| End Date: | March 1, 2020 |
| Contact: | Miko Yu |
| Email: | mey2006@med.cornell.edu |
| Phone: | 212-746-1496 |
The purpose of this study is collect observational data regarding patterns of care and
outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity
focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation,
photodynamic therapy, and brachytherapy.
outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity
focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation,
photodynamic therapy, and brachytherapy.
Through the use of a prospective registry, the investigators will collect information on
patient characteristics including age, co-morbidities, imaging and biopsy information, and
prior treatments. Information on treatment details will also be captured, including treatment
time, anesthesia delivered, and length of stay, when applicable. Oncologic outcomes including
PSA, post-treatment biopsy and imaging data, need for re-treatment, and survival outcomes
will also be captured. Safety outcomes will be captured using the Clavien-Dindo
classification scale, and additional specific GU complications will be recorded, which
include urinary retention, urethral stricture, recto-urethral fistula, osteomyelitis, and
urinary tract infection. Finally, the investigators will capture functional outcomes using
health related quality of life questionnaires including the EPIC questionnaire, IIEF-5,
MSHQ-EjD, and IPSS.
patient characteristics including age, co-morbidities, imaging and biopsy information, and
prior treatments. Information on treatment details will also be captured, including treatment
time, anesthesia delivered, and length of stay, when applicable. Oncologic outcomes including
PSA, post-treatment biopsy and imaging data, need for re-treatment, and survival outcomes
will also be captured. Safety outcomes will be captured using the Clavien-Dindo
classification scale, and additional specific GU complications will be recorded, which
include urinary retention, urethral stricture, recto-urethral fistula, osteomyelitis, and
urinary tract infection. Finally, the investigators will capture functional outcomes using
health related quality of life questionnaires including the EPIC questionnaire, IIEF-5,
MSHQ-EjD, and IPSS.
Inclusion Criteria:
- >18 years of age
- Undergoing focal therapy for primary or salvage treatment of prostate cancer, or
- Have received prior focal therapy
Exclusion Criteria:
- Clinically-evident metastatic disease
- Unable to fill out an English-language questionnaire
We found this trial at
1
site
New York, New York 10065
Principal Investigator: Jim C Hu, M.D., M.P.H.
Phone: 212-746-1496
Click here to add this to my saved trials
